The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
 
Atsushi Ishiguro
No Relationships to Disclose
 
Hiroshi Nakatsumi
Honoraria - Bayer Yakuhin; Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical; Viatris
 
Kazuaki Harada
Speakers' Bureau - Bayer; Bristol Myers Squibb; DAIICHI SANKYO COMPANY, LIMITED; Lilly; Merck Serono; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kentaro Sawada
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Takayuki Ando
Honoraria - Bristol-Myers Squibb Company; DAIICHI SANKYO COMPANY, LIMITED.; Lilly Japan; Merck; Miyarisan pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Yusuke Sasaki
No Relationships to Disclose
 
Ayumu Yoshikawa
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masayoshi Dazai
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Osamu Muto
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly; Takeda; Yakult Honsha
 
Tamotsu Sagawa
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Ryo Takagi
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - EPS Associates Co., Ltd.
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha